Let's start with CSL's leadership change, because it sets the tone. Paul McKenzie has stepped down as chief executive, and the board has appointed long-time CSL executive and current director Gordon ...

The Australian sharemarket has hit a 50-day high as investors sent shares soaring in some of the bourse’s biggest companies after they beat expectations in their profit results. Commonwealth Bank and ...

Good morning, everyone. Thank you for joining CSL's results presentation for the first half of the 2026 financial year. I'm Mark Dehring, CSL's Head of Investor Relations. Please note, this briefing ...

CSL names Gordon Naylor as interim CEO after Dr Paul McKenzie's retirement, marking a new chapter for the ASX healthcare leader. Dr Paul McKenzie will retire as CEO and managing director, effective 10 ...

Australian pharmaceuticals heavyweight CSL has announced its chief executive Dr Paul McKenzie is retiring with immediate effect, as the company tries to rebuild confidence among investors following a ...

With pressure piling on for CSL, the Australian vaccine and plasma specialist has elected to part ways with its CEO on the eve of its latest earnings announcement. Paul McKenzie, Ph.D., who’s served ...

CSL taps ex-vaccine division head Gordon Naylor as interim CEO Appointment of Naylor is a salvage mission, says analyst CSL shares close 5% lower; co to report HY results on Wed Feb 10 (Reuters) - ...

Chairman and former boss Brian McNamee has claimed the departing CEO didn’t have the skills to steer the global biotech’s future. The turmoil at the top adds to a horror six months for CSL. In that ...

The ASX 200 closed slightly lower, and the CSL chief executive stepped down abruptly ahead of tomorrow's half-year results. Catch up on the day's events and insights from our business reporters on the ...

John is a writer at Pocket-lint. He is passionate about all things technology, and is always keeping up with the latest smartphone and PC releases. John has previously written at MobileSyrup. When ...

Given its struggles over the past couple of years, it has been tempting to sell CSL Ltd (ASX: CSL) shares on numerous occasions. However, I'm hoping to never sell the biotechnology giant's shares. The ...

In the latest escalation of the long-running dispute, up to 1270 workers will walk out of CSL’s Melbourne office, expressing anger at management’s response to union members voting down the company’s ...